Trial Profile
A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF, A Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With 5-Fluorouracil and Leucovorin Chemotherapy in Subjects With Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First-Line CPT-11.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 24 Sep 2005 New trial record.
- 01 Jun 2005 Primary endpoint 'Overall survival duration' has not been met.